Investing.com - Avid Bioservices reported on Tuesday second quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Avid Bioservices announced earnings per share of $-0.01 on revenue of $34.76M. Analysts polled by Investing.com anticipated EPS of $0.01 on revenue of $32.05M.
Avid Bioservices shares are down 49% from the beginning of the year and are trading at $14.88 , down-from-52-week-high.
Avid Bioservices follows other major Healthcare sector earnings this month
Avid Bioservices's report follows an earnings beat by AstraZeneca ADR on Thursday, November 10, 2022, who reported EPS of $1.67 on revenue of $10.98B, compared to forecasts EPS of $0.77 on revenue of $10.78B.
Medtronic had beat expectations on Tuesday, November 22, 2022 with second quarter EPS of $1.3 on revenue of $7.6B, compared to forecast for EPS of $1.28 on revenue of $7.7B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar